Cybin Provides Corporate Update And Highlights Upcoming Clinical Milestones; Initiation Of Pivotal CYB003 Phase 3 Study In MDD Expected In Mid-2024; Phase 2 Topline Efficacy And Safety Results For CYB004 In Generalized Anxiety Disorder Expected Q4 2024
Portfolio Pulse from Benzinga Newsdesk
Cybin Inc. (CYBN) announced updates on its clinical programs, including the expected initiation of a Phase 3 study for CYB003 in MDD by mid-2024 and Phase 2 results for CYB004 in GAD by Q4 2024. The company secured a $150 million funding round and received FDA Breakthrough Therapy Designation for CYB003. CYB003 showed promising Phase 2 results in MDD treatment, and CYB004 is in development for GAD, with a Phase 2 study underway. Cybin's intellectual property portfolio includes over 50 granted patents and 170 pending applications related to psychedelic-based treatments.
May 06, 2024 | 12:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cybin Inc. is advancing with its clinical programs CYB003 and CYB004, supported by a recent $150 million funding and FDA Breakthrough Therapy Designation for CYB003. Phase 3 study for CYB003 in MDD and Phase 2 results for CYB004 in GAD are expected to be significant milestones.
The recent funding round and FDA Breakthrough Therapy Designation for CYB003 highlight strong financial and regulatory support for Cybin's clinical programs. These developments are likely to positively impact investor sentiment and the company's stock price in the short term, as they demonstrate progress in Cybin's pipeline and potential for commercial success.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100